Finasteride vs Minoxidil: What Actually Changes

Finasteride and topical minoxidil are different tools for male pattern hair loss. Finasteride works on the DHT pathway involved in follicle miniaturisation. Topical minoxidil supports the hair-growth cycle. The better question is whether the pattern fits androgenetic alopecia, what outcome you want to measure, and which safety tradeoffs you can accept.

Finasteride vs minoxidil sounds like a straight contest. It is not.

Male pattern hair loss, also called androgenetic alopecia, is usually a slow pattern: temples, hairline, mid-scalp, crown, or vertex. Australian Prescriber describes pattern hair loss as genetically regulated, driven by sensitivity to androgens, and associated with follicle miniaturisation and changes in the hair cycle. Healthdirect describes male pattern baldness as common, genetic, and affecting about half of men over 40.

That matters because both medicines are pattern-hair-loss tools. They do not replace diagnosis. They do not treat every shedding episode. And they are not cosmetic shortcuts for scalp disease, patchy alopecia, nutritional deficiency, thyroid disease, medication-related shedding, traction injury, fungal infection, or scarring hair loss.

The useful first question is not "which medicine is stronger?" It is "does this look like the problem these medicines are meant to address?"

Male pattern hair loss usually has a recognisable shape. The hairline may recede at the temples. The crown may thin. The mid-scalp may become less dense. The scalp is usually not painful, crusted, scarred, or inflamed. The change is usually gradual rather than overnight.

Other hair-loss patterns need a different conversation:

If the pattern does fit androgenetic alopecia, finasteride and topical minoxidil still do different jobs.

The table is deliberately practical. A medicine that is theoretically effective but not tolerated, not used consistently, or used for the wrong diagnosis is not a good plan.

Finasteride acts upstream. It inhibits type II 5-alpha-reductase, an enzyme involved in converting testosterone to dihydrotestosterone, or DHT.

DHT is one of the main drivers of follicle miniaturisation in genetically susceptible men. Miniaturised follicles produce shorter, finer hairs. Over time, density drops because thick terminal hairs become finer vellus-like hairs and the growth phase becomes less productive.

Medicine Finder product information for Finasteride-WGR 1 mg says the medicine is indicated for male pattern hair loss to increase hair growth and prevent further hair loss in men 18 years or older. It also says efficacy has not been demonstrated in men over 41 years in that listed product information, and that it is not indicated for women or children.

Useful expectations:

• It is usually a daily medicine.
• It is not an immediate hair-thickening product.
• Daily use for at least three months may be needed before increased growth or prevention of further loss is noticed.
• Continued use is usually needed to maintain benefit.
• It is usually about slowing progression and preserving miniaturising hair, not recreating a teenage hairline.

Finasteride product information is medicine-specific. Different brands can have their own consumer medicine information, but the key prescription-only and pregnancy-handling boundaries still matter when discussing finasteride as a class.

Finasteride is prescription-only for a reason. The decision is not simply "does it work?" The decision is whether the expected benefit is worth the individual risk.

Some side effects are uncommon, but the discussion still matters because they are high-salience for the person making the decision. Medicine Finder consumer information for finasteride lists difficulty achieving an erection, reduced desire for sex, breast symptoms, testicular pain, blood in semen, and depression among possible side effects or serious side effects. Product information also warns that PSA interpretation can be affected.

This is where a good comparison stays adult: someone may reasonably accept those risks; someone else may not.

Topical minoxidil acts more locally. It is applied to the scalp, usually as foam or solution. The exact hair-growth mechanism is not fully understood, but Australian Prescriber describes minoxidil as a vasodilator thought to improve blood flow to the follicle and promote hair growth.

Common topical minoxidil products are easier to access than finasteride because they can be Pharmacy Medicines. That does not make them consequence-free. It means the first safety filter often happens through pharmacy advice and product instructions rather than a prescription consult.

Timeline

View larger image

Early shedding, slow growth cycles, and inconsistent photos can hide whether a treatment is helping.

Useful expectations:

• It needs consistent scalp application.
• It should be applied to a healthy, intact scalp.
• Early shedding can happen and may be temporary.
• At least four months may be needed before visible evidence of hair regrowth.
• Stopping usually means losing gained hair and returning toward the previous pattern.
• It works best where follicles are still present. A shiny bald scalp is a different context.

Topical minoxidil is often framed as the "simple" option. It can be simple. It can also be annoying, irritating, messy, or unsuitable.

Medicine Finder information for men's Regaine Extra Strength Foam says to stop use and seek medical advice for hypotension, chest pain, rapid heartbeat, faintness or dizziness, sudden unexplained weight gain, swollen hands or feet, or persistent scalp redness or irritation.

Hair growth is slow. The mistake is judging either medicine after a few weeks, especially if minoxidil shedding has started or the haircut has changed.

Photo discipline matters. Hair looks different after styling, sweating, a haircut, bathroom downlights, or wet combing. If the review photos are not comparable, the conclusion is weak.

Combination treatment is common because the mechanisms differ. Finasteride targets the androgen signal. Minoxidil supports follicle cycling and visible growth activity. Australian Prescriber notes combination therapy is commonly employed and that introductory treatment regimens for male pattern hair loss can include topical minoxidil with oral finasteride.

That still does not make combination treatment the default for every person.

A clean trial is underrated. If someone is side-effect anxious, starting two things at once can create more uncertainty, not less. If someone is already losing density quickly and understands the risks, a combined plan may be reasonable under medical guidance.

Telehealth can be suitable for some hair-loss assessments because a doctor can review history, pattern photos, medicines, medical conditions, side-effect risk, and goals. It is not suitable for every scalp problem.

The remote-versus-in-person decision is not a judgment on convenience. It is a clinical suitability decision.

This is the comparison most people actually need.

Finasteride and minoxidil sit in different supply categories. TGA scheduling basics describe Schedule 2 as Pharmacy Medicine and Schedule 4 as Prescription Only Medicine. The current Poisons Standard is the national scheduling instrument given effect through state and territory legislation.

For this comparison:

• Finasteride 1 mg hair-loss products are prescription-only medicines.
• Common topical minoxidil products are pharmacy medicines.
• Oral minoxidil is a prescription-only medicine and is off label for hair loss.
• Dutasteride is also prescription-only and is used off label for hair loss in some specialist contexts.
• Prescription-only medicine advertising rules are stricter than ordinary consumer product advertising.

This is why good educational content can name medicines, explain risks, and link to official sources, but it should not read like an ad for a prescription medicine.

Finasteride and minoxidil do not compete in a single lane.

Finasteride is the DHT-pathway question: diagnosis, systemic risks, sexual and mood side effects, pregnancy-handling precautions, PSA interpretation, and prescription review.

Topical minoxidil is the growth-cycle and routine question: scalp tolerance, application consistency, early shedding, product transfer, blood-pressure or heart symptoms, and long-term use.

The best comparison is not "which one wins?" It is:

1. 1

   Does the pattern fit androgenetic alopecia?

2. 2

   What outcome are you trying to measure: slowing loss, regrowth, or both?

3. 3

   Which safety tradeoffs are acceptable?

4. 4

   Can you follow the routine long enough to judge it?

5. 5

   What would make you stop, reassess, or seek in-person care?

If those questions are clear, the medicine choice becomes less mysterious.

• Healthdirect: Male pattern baldness
• Healthdirect: Alopecia (hair loss)
• Australian Prescriber: Male and female pattern hair loss
• Australian Commission on Safety and Quality in Health Care Medicine Finder: Finasteride-WGR 1 mg
• Australian Commission on Safety and Quality in Health Care Medicine Finder: Men's Regaine Extra Strength Foam
• Therapeutic Goods Administration: Scheduling basics of medicines and chemicals in Australia
• Therapeutic Goods Administration: The Poisons Standard
• Therapeutic Goods Administration: What can and cannot be advertised to the general public